Drugs / HH160
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07623369 | Jun 2026 → Aug 2028 expected | cervical cancer, colorectal cancer, endometrial cancer, gastroesophageal adenocarcinoma +7 | Huahui Health | Not yet recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2026-06-30 | Huahui Health | Regulatory Huahui Health Receives NMPA Clearance for HH160 Phase I Clinical Trial in China huahuihealth.com ↗
Huahui Health today announced that HH160, its proprietary novel trispecific antibody in oncology immunotherapy, has received clearance from the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) to initiate a Phase I clinical trial (HH160-101) in China. |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-06-30 | Huahui Health | Huahui Health Receives NMPA Clearance for HH160 Phase I Clinical Trial in China huahuihealth.com ↗ |
| 2026-04-27 | Huahui Health | Huahui Health and BeOne Medicines Enter into a Global Exclusive Option, License and Collaboration Agreement for Innovative Oncology Drug HH160 huahuihealth.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HH160 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07623369 ↗ |
| Route | Intravenous | “Administered by intravenous infusion every 3 weeks (Q3W)” NCT07623369 ↗ |